78.13
-0.19 (-0.24%)
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
Stock | Intra-Cellular Therapies Inc. | Bearish | Bullish |
Stockmoo Score
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Investment Style | Small Growth |
52 Weeks Range | ||
Price Target Range | ||
High | 130.00 (Cantor Fitzgerald, 66.39%) | Buy |
Median | 100.00 (27.99%) | |
Low | 74.00 (Goldman Sachs, -5.29%) | Hold |
Average | 97.22 (24.43%) | |
Total | 7 Buy, 2 Hold | |
Avg. Price @ Call | 74.79 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Piper Sandler | 06 Sep 2024 | 92.00 (17.75%) | Buy | 73.20 |
JP Morgan | 21 Aug 2024 | 81.00 (3.67%) | Buy | 75.69 |
12 Jun 2024 | 78.00 (-0.17%) | Buy | 68.20 | |
Cantor Fitzgerald | 08 Aug 2024 | 130.00 (66.39%) | Buy | 74.42 |
14 Jun 2024 | 120.00 (53.59%) | Buy | 67.77 | |
Goldman Sachs | 08 Aug 2024 | 74.00 (-5.29%) | Hold | 74.42 |
Needham | 08 Aug 2024 | 100.00 (27.99%) | Buy | 74.42 |
22 Jul 2024 | 100.00 (27.99%) | Buy | 76.48 | |
RBC Capital | 08 Aug 2024 | 106.00 (35.67%) | Buy | 74.42 |
25 Jun 2024 | 103.00 (31.83%) | Buy | 72.42 | |
UBS | 08 Aug 2024 | 79.00 (1.11%) | Hold | 74.42 |
25 Jun 2024 | 83.00 (6.23%) | Hold | 72.42 | |
Mizuho | 21 Jun 2024 | 100.00 (27.99%) | Buy | 76.58 |
Canaccord Genuity | 20 Jun 2024 | 113.00 (44.63%) | Buy | 75.55 |
Show more |
Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
---|---|---|---|---|
MATES SHARON | - | 73.71 | -95,925 | -7,064,498 |
Aggregate Net Quantity | -95,925 | |||
Aggregate Net Value ($) | -7,064,498 | |||
Aggregate Avg. Buy ($) | - | |||
Aggregate Avg. Sell ($) | 73.71 |
Name | Holder | Date | Type | Quantity | Price | Value ($) |
---|---|---|---|---|---|---|
MATES SHARON | Officer | 28 Aug 2024 | Automatic sell (-) | 32,699 | 72.77 | 2,379,506 |
MATES SHARON | Officer | 28 Aug 2024 | Option execute | 32,699 | - | - |
MATES SHARON | Officer | 27 Aug 2024 | Automatic sell (-) | 40,513 | 73.88 | 2,993,100 |
MATES SHARON | Officer | 27 Aug 2024 | Option execute | 40,513 | - | - |
MATES SHARON | Officer | 26 Aug 2024 | Automatic sell (-) | 22,713 | 74.49 | 1,691,891 |
MATES SHARON | Officer | 26 Aug 2024 | Option execute | 22,713 | - | - |
Date | Type | Details |
---|---|---|
28 Aug 2024 | Announcement | Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences |
08 Aug 2024 | Announcement | Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference |
07 Aug 2024 | Announcement | Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer |
07 Aug 2024 | Announcement | Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance |
24 Jul 2024 | Announcement | Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast |
18 Jun 2024 | Announcement | Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder |
10 Jun 2024 | Announcement | Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |